ConductScience.org, home

Paper36909127

Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis.

Magalhães D and 3 others. Cureus, 2023. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis. Papers, record 36909127. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36909127

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis.
PubMed
Journal
Cureus
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.92
iCite
Revised in PubMed
2023-03-14
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Magalhães DDenise
2Dos Santos JJoana
3Frutuoso AAmaro
4Mesquita AAlexandra

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References57

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111900227HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity.Cancer2002https://conductscience.org/library/papers/11900227PubMed
231876547Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.Curr Opin Oncol2020https://conductscience.org/library/papers/31876547PubMed
329018945[Nuclear Her2 expression in hepatocytes in liver disease].Pathologe2017https://conductscience.org/library/papers/29018945PubMed
435148934Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.Breast2022https://conductscience.org/library/papers/35148934PubMed
532402160Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.N Engl J Med2020https://conductscience.org/library/papers/32402160PubMed
622153890
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Lancet Oncol2012https://conductscience.org/library/papers/22153890PubMed
711597398The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.Eur J Cancer2001https://conductscience.org/library/papers/11597398PubMed
835665782Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.N Engl J Med2022https://conductscience.org/library/papers/35665782PubMed
911248153Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med2001https://conductscience.org/library/papers/11248153PubMed
107894139C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study.Histol Histopathol1994https://conductscience.org/library/papers/7894139PubMed
111374219Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver.Am J Clin Pathol1992https://conductscience.org/library/papers/1374219PubMed
1225279210
Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis.
Mol Clin Oncol2014https://conductscience.org/library/papers/25279210PubMed
1320728210
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet2010https://conductscience.org/library/papers/20728210PubMed
1431825192Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.N Engl J Med2020https://conductscience.org/library/papers/31825192PubMed
1518650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
1615858121Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.J Clin Pathol2005https://conductscience.org/library/papers/15858121PubMed
1721741829Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.Eur J Cancer2011https://conductscience.org/library/papers/21741829PubMed
1810880430The ErbB signaling network: receptor heterodimerization in development and cancer.EMBO J2000https://conductscience.org/library/papers/10880430PubMed
1916557381Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.J Cancer Res Clin Oncol2006https://conductscience.org/library/papers/16557381PubMed
2029420221Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study.Clin Cancer Res2018https://conductscience.org/library/papers/29420221PubMed

See all 57 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
41710748Peptide-Functionalized Liposomal Nanocarriers for Targeted Therapy of Liver Fibrosis and Hepatocellular Carcinoma: Design, Mechanisms, and Clinical Prospects.ACS Pharmacol Transl Sci2026https://conductscience.org/library/papers/41710748PubMed
41641648A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series.Cancer Med2026https://conductscience.org/library/papers/41641648PubMed
40599803Decoding the therapeutic mechanism of Conocarpus lancifolius in hepatocellular carcinoma: network pharmacology, molecular docking, and LC-MS QTOF insights.Front Pharmacol2025https://conductscience.org/library/papers/40599803PubMed
40028484Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma.J Liq Biopsy2023https://conductscience.org/library/papers/40028484PubMed
39524833Network pharmacology and bioinformatic integrative analysis reveals candidate gene targets and potential therapeutic of East Kalimantan propolis against hepatocellular carcinoma.Heliyon2024https://conductscience.org/library/papers/39524833PubMed
39335117Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas.Cancers (Basel)2024https://conductscience.org/library/papers/39335117PubMed
37293382Bioinformatics and network pharmacology-based study to elucidate the multi-target pharmacological mechanism of the indigenous plants of Medina valley in treating HCV-related hepatocellular carcinoma.Saudi Pharm J2023https://conductscience.org/library/papers/37293382PubMed

Download CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36909127

GET https://conductscience.org/api/papers/v1/36909127/references?page=2